Lofexidine — Membership Pricing

Other medications in Addiction Medicine

• Nalmefene
• Nicotine Inhaler

About Lofexidine

Lofexidine is a non-opioid medication designed to help ease the challenging symptoms of opioid withdrawal. Facing withdrawal can be daunting, and the cost of necessary medications shouldn't add to the burden. TheDrugClub is dedicated to making essential prescriptions like lofexidine more accessible and affordable for our members, ensuring you can focus on your health.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Lofexidine is approved for (FDA label)

Lofexidine tablets are indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. Lofexidine tablets are a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

Source: Read the full FDA label on DailyMed. Label effective date: May 21, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Lofexidine (FDA label)

Lofexidine tablets are available as round, concave-shaped, peach-colored, film-coated tablets, debossed with “C” on one side and “71” on other side. Each tablet contains 0.18 mg lofexidine (equivalent to 0.2 mg of lofexidine hydrochloride). Tablets: 0.18 mg.

Source: FDA prescribing information (DailyMed). Set ID: ce4488e2-842c-45ba-aca7-075a900e2a1c. SPL document ID: f742254f-781e-4e7a-ae0b-e79b8482980d. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Lofexidine (FDA label)

The following serious adverse reactions are described elsewhere in labeling: • Hypotension, Bradycardia, and Syncope [see Warnings and Precautions ( 5.1 )] • QT Prolongation [see Warnings and Precautions ( 5.2 )] • Central Nervous System Depression [see Warnings and Precautions ( 5.3 )] • Opioid Overdose [see Warnings and Precautions ( 5.4 )] • Discontinuation Symptoms [see Warnings and Precautions ( 5.5 )] Most common adverse reactions (incidence ≥ 10% and notably more frequent than placebo) are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Indoco Remedies Limited at 1-833-856-0880 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to adverse reaction rates observed for another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: ce4488e2-842c-45ba-aca7-075a900e2a1c. SPL document ID: f742254f-781e-4e7a-ae0b-e79b8482980d. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Lofexidine (FDA label)

Risk of Hypotension, Bradycardia, and Syncope: May cause a decrease in blood pressure, a decrease in pulse, and syncope. Monitor vital signs before dosing and advise patients on how to minimize the risk of these cardiovascular effects and manage symptoms, should they occur. Monitor symptoms related to bradycardia and orthostasis. When using in outpatients, ensure that patients are capable of self-monitoring for signs and symptoms. Avoid use in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure, as well as in patients with marked bradycardia. ( 5.1 ) Risk of QT Prolongation: L o fexidine tablets prolong the QT interval. Avoid use in patients with congenital long QT syndrome.

Source: FDA prescribing information (DailyMed). Set ID: ce4488e2-842c-45ba-aca7-075a900e2a1c. SPL document ID: f742254f-781e-4e7a-ae0b-e79b8482980d. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Lofexidine (FDA label)

Methadone : Methadone and Lofexidine tablets both prolong the QT interval. ECG monitoring is recommended when used concomitantly. ( 7.1 ) Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. ( 7.2 ) CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine. Monitor for symptoms of orthostasis and bradycardia with concomitant use of a CYP2D6 inhibitor. ( 7.4 ) 7.1 Methadone Lofexidine tablets and methadone both prolong the QT interval. ECG monitoring is recommended in patients receiving methadone and Lofexidine tablets concomitantly [see Warnings and Precautions ( 5.2 ), Clinical Pharmacology ( 12.3 )]. 7.2 Oral Naltrexone Coadministration of Lofexidine tablets and oral naltrexone resulted in statistically significant differences in the steady-state pharmacokinetics of naltrexone. It is possible that oral naltrexone efficacy may be reduced if used concomitantly within 2 hours of Lofexidine tablets.

Source: FDA prescribing information (DailyMed). Set ID: ce4488e2-842c-45ba-aca7-075a900e2a1c. SPL document ID: f742254f-781e-4e7a-ae0b-e79b8482980d. Label effective date: May 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.